News

Video

A Phase 0/1 ‘Trigger’ Trial of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Patients With EGFR Alterations or Fusions

Author(s):

Nader Sanai, MD

Dr. Nader Sanai presents the findings of a phase 0/1 trigger trial (NCT06072586) that evaluates the CNS penetration of BDTX-1535 in patients with recurrent high-grade gliomas and EGFR mutations.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Related Content
TLX101 in Recurrent High-Grade Glioma | Image Credit: © peterschreiber.media– stock.adobe.com
April 16th 2025

TLX101 Has Preliminary Safety and Clinical Activity in Recurrent High-Grade Glioma

Drs Camidge and Boire discuss Dr Boire's journey to becoming a physician-scientist, moments in her career that shaped her fascination with neurology, and how studying human biology at the cellular level can ultimately help improve the lives of patients with cancer.
January 22nd 2025

A Nuanced Understanding of Cellular Biology Advances Neuro-Oncology Practice: With D. Ross Camidge, MD, PhD; and Adrienne A. Boire, MD, PhD

Solid tumors | Image Credit: © Katsyarina – stock.adobe.com
April 9th 2025

FDA Clears ZEISS INTRABEAM 700 for Intraoperative Radiation Therapy in Neuro-Oncology & Breast Cancer

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

US FDA
April 3rd 2025

FDA Gives RPDD to NEO100 for Pediatric-Type Diffuse High-Grade Glioma

Reduced Radiotherapy Margins in High-Grade Glioma | Sebastian Kaulitzki – stock.adobe.com
March 24th 2025

Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG